Peptide-Based Nootropic Research
Selank and Semax are two synthetic peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both peptides are based on naturally occurring regulatory peptides — Selank derives from the immunomodulatory peptide tuftsin, while Semax is an analogue of the ACTH(4-10) fragment. Their development represents a fascinating approach to neuroscience research: using the body own regulatory peptide sequences as templates for synthetic analogues with enhanced stability and potency.
Selank: From Tuftsin to Anxiolytic Research
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide that incorporates the tuftsin sequence (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension that enhances metabolic stability. Tuftsin is a naturally occurring tetrapeptide released from IgG heavy chain cleavage by spleen enzymes, and is known for its immunomodulatory properties.
GABAergic modulation: Research suggests Selank may influence the GABAergic system, potentially modulating the balance between excitatory and inhibitory neurotransmission. Studies have reported effects on GABA receptor subunit expression in animal models.
BDNF expression: Several studies have investigated Selank effects on brain-derived neurotrophic factor (BDNF) — a key neurotrophin involved in synaptic plasticity, learning, and memory. Published research reports associations between Selank administration and altered BDNF mRNA expression in specific brain regions.
Enkephalin degradation: Selank has been reported to inhibit enzymes involved in enkephalin degradation, potentially influencing endogenous opioid peptide signaling without direct opioid receptor activation.
Semax: ACTH Fragment Research
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the ACTH(4-10) fragment. The parent sequence ACTH(4-10) (Met-Glu-His-Phe-Arg-Trp-Gly) was identified in early research as the minimal fragment of ACTH retaining neurotrophic activity independent of adrenocortical stimulation. Semax modified sequence enhances stability while maintaining neurotrophic activity.
Neurotrophic factor regulation: Published research associates Semax administration with increased expression of BDNF, NGF, and other neurotrophins in animal models. These effects appear to be mediated through melanocortin receptor-independent pathways.
Cerebrovascular research: Semax has been studied in animal models of cerebral ischemia, with some publications reporting associations with reduced infarct volume and improved neurological outcomes.
Gene expression studies: Transcriptomic analyses have revealed that Semax administration affects the expression of hundreds of genes in the rat brain, spanning immune response, neurotransmission, and vascular function pathways.
Research Considerations
Both peptides are well-suited for in vitro and in vivo neuroscience research. They are water-soluble, relatively stable in solution, and have well-characterized molecular weights (~751 Da for Selank, ~813 Da for Semax) that are easily verified by mass spectrometry.
CertaPeptides supplies both Selank (5mg and 10mg) and Semax (5mg and 10mg) with ≥99% HPLC purity and batch COAs.
Strictly for research purposes. Not intended for human consumption or therapeutic use.